Reduced levels for STAT3, downstream phospho-Akt, β-catenin, androgen receptor, the antiapoptotic proteins Bcl-xL and Mcl-1, and microRNAs deregulated in prostate cancer. This evidence concerns the gene BCL2L1 and prostate carcinoma.